By Peter Laird, MD
Dr. Ajay Singh started The Kidney Doctor blog recently and has already developed discussions on many important renal related topics. In addition to his own, posts, he has had several top experts post on selected topics. Participation with follow up comments is perhaps the most active at this time of any online renal blog. Interestingly, diverse opinions are the norm in the comment section of the The Kidney Doctor making the intersection between professional nephrologists to ordinary patients a rare phenomenon not encountered on most blogs. This lends itself to extreme positions at times. One example is by Noshi Ishak, MD of Laconia, NH where he coined the phrase "Extra Cheese Dialysis" in response to the negative findings of the FHN nocturnal study, but improved phosphorus control:
Dialysis Unplugged: "Waiting for Godot"
I hope CMS and the FDA will keep its eyes open and will not be sucked into another Amgen like scheme. Our country is deep in debt and has no money to waist on “Extra Cheese Dialysis”.
If ever the FDA will give any guidelines for hemodialysis under the information we have today it should be as follows:
1. All patients are to be dialyzed 3x/week, whether in center or at home, and the duration of the treatment and choice of dialyzer are to be prescribed by their Nephrologists in order to achieve the recommended clearances and adequate fluid removal according to the patient’s needs and body size.
2. For transplant candidates with expected prolonged wait for an organ and patients who failed their transplants, a more intensive dialysis such as daily dialysis or daily nocturnal dialysis is recommended.
The logic behind his comment is an analogy to the EPO debacle where the industry utilized higher doses for the benefit of huge profits at the expense of patient outcomes. Although, the EPO over utilization in American dialysis institutions is well documented, Dr. Ishak, is over looking several issues in what in my opinion is a false analogy.
First, he stated that most studies have not shown any improvement in mortality with nocturnal "extra cheese hemodialysis," which is not a factual statement. A recent study by Pauly in 2009 showed equivalent mortality between Nocturnal Home Hemodialysis (NHHD) and cadaveric transplant:
Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients
Results. The total study population consisted of 177 NHD patients matched to 1062 DTX and LTX recipients (total 1239 patients) followed for a maximum of 12.4 years. During the follow-up period, the proportion of deaths among NHD, DTX and LTX patients was 14.7%, 14.3% and 8.5%, respectively (P = 0.006). We found no difference in the adjusted survival between NHD and DTX (HR 0.87, 95% CI 0.50–1.51; NHD reference group), while LTX survival was better (HR 0.51, 95% CI 0.28–0.91).
Conclusions. These results indicate that NHD and DTX survival is comparable, and suggest that this intensive dialysis modality may be a bridge to transplantation or even a suitable alternative in the absence of LTX in the current era of growing transplant waiting lists and organ shortage.
Secondly, Dr. Ishak incorrectly states that nocturnal home hemodialysis is more expensive than standard in-center hemodialysis which has never been the case. Richard Rettig noted that home hemodialysis in the 1970's was a little over $14,000 for the first year and $7000 each year thereafter while in-center patients averaged around $29,000 with much inferior outcomes. Northwest Kidney Centers is one of the most outspoken advocates of more frequent and longer duration dialysis and their experience is that home hemodialysis patients save over 40% in expenses compared to in-center patients:
Home Hemodialysis --- The Best Dialysis Treatment
Even so, for-profit corporations have neglected the financial advantages of home hemodialysis although these have been known for 40 years. For example, in the Northwest Kidney Centers’ program,the cost of providing hemodialysis in the home is only approximately 60% of the cost of dialysis in the facility. Finally, Da Vita, one of the two largest dialysis corporations, has begun to encourage home hemodialysis aggressively.
Europe, Japan and Australia routinely encourage nocturnal home hemodialysis and their programs enjoy significant cost savings compared to our for-profit dominated dialysis industry with signifcantly improved outcomes at the same time. The dose response curve of optimal hemodialysis does not show the deleterious effects of higher EPO dosages. That is the critical flaw of Dr. Ishak's analogy. In fact, modern era NHHD started in Toronto in the 1990's came about as a treatment option for patients with severe cardiac conditions who did not tolerate short, violent sessions with high ultrafiltration rates. Patients with severe co-morbidities often thrive with more frequent and gentler dialysis sessions.
Thirdly, Dr. Ishak advised selected use of frequent home hemodialysis to those with limited co-morbidities and transplant eligibility. Rich Berkowitz is one of the patients he would exclude from NHHD. Rich readily testifies that he would not be alive today without the benefit of NHHD on the NxStage System One. Several years ago, on the way home from a conventional in-center dialysis session, Rich experienced a severe heart attack and nearly died. Today, he is a leading dailysis advocate still kicking way beyond any discernible life expectancies of a dialysis patient at his age and with his medical history. Dr. Ishak would pull the plug on his home hemodialysis. Bill Peckham suffered from FSGS and a failed early transplant from his brother. After over 20 years on dialysis, Dr. Ishak would pull the plug on Bill and condemn him to standard in-center suboptimal clearances completely ignoring the benefits of his home hemodialysis that allows him to continue to work full time in a difficult and physically demanding job.
Lastly, Dr. Ishak is guilty in my opinion of not employing the standards of evaluating the value of any given study taking into account it's strength and weaknesses. Yes, the FHN nocturnal study failed to reach the expected outcomes, but that is due to serious internal flaws of the study, (here, here, and here) not the dialysis modality itself. There is no adverse increased dose response with dialysis, just the opposite, more dialysis is better dialysis. Home dialysis patients with CHF, LVH and cardiovascular limitations are ideal candidates for longer and slower treatments. I would hope that Dr. Ishak is in the minority opinion in America, but after forty years of a concerted effort to over come the for-profit dominated American market, he unfortunately is most likely just the tip of an iceberg.
Sadly, the American nephrologist is more often than not the nemesis to optimal dialysis when they should instead be our chief advocate. Thankfully, many remain vigilent in this long and protracted battle waged against the illogical conclusions of American nephrologists that ignore decades of positive findings in study after study of optimal dialysis. We have an uphill battle but the truth in the end shall prevail. Despite the null and void outcomes of the FHN nocturnal study, there are other studies still in the pipeline outside of the United States that will hopefully put this hegemony to rest once and for all. Dr. Ishak should also include one more group in his flawed assessment, the American nephrologist who overwhelmingly chooses NHHD when they themselves are in need of renal replacement therapy.
Extra cheese dialysis? No my friend, NHHD is life saving, cost cutting and what should be America's gold standard dialysis modality as it is in so many other nations. Perhaps one day, the American nephrologist will have eyes to see what the rest of the world has recognized for decades. More dialysis is better dialysis.
Recent Comments